Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 6
2018 5
2019 6
2020 5
2021 5
2022 1
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Targeted treatment of advanced NRAS-mutated melanoma.
Koelblinger P, Dummer R. Koelblinger P, et al. Oncotarget. 2017 Sep 29;8(49):84616-84617. doi: 10.18632/oncotarget.21388. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156659 Free PMC article. No abstract available.
[Rückblick: ÖGDV Jahrestagung 2022].
Koelblinger P, Bauer JW. Koelblinger P, et al. J Dtsch Dermatol Ges. 2023 May;21(5):567-568. doi: 10.1111/ddg.15082_g. J Dtsch Dermatol Ges. 2023. PMID: 37183742 German. No abstract available.
MEK inhibition and immune responses in advanced melanoma.
Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque MP, Koelblinger P. Dummer R, et al. Among authors: koelblinger p. Oncoimmunology. 2017 Aug 10;6(8):e1335843. doi: 10.1080/2162402X.2017.1335843. eCollection 2017. Oncoimmunology. 2017. PMID: 28919996 Free PMC article. Review.
Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.
Lang R, Welponer T, Richtig E, Wolf I, Hoeller C, Hafner C, Nguyen VA, Kofler J, Barta M, Koelblinger P, Hitzl W, Emberger M, Laimer M. Lang R, et al. Among authors: koelblinger p. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1799-1810. doi: 10.1111/jdv.19218. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37210651 Clinical Trial.
Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma.
Ayati N, Jamshidi-Araghi Z, Hoellwerth M, Schweighofer-Zwink G, Hitzl W, Koelblinger P, Pirich C, Beheshti M. Ayati N, et al. Among authors: koelblinger p. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2715-2726. doi: 10.1007/s00259-023-06247-8. Epub 2023 May 4. Eur J Nucl Med Mol Imaging. 2023. PMID: 37140669 Free PMC article.
37 results